Sun Pharmaceutical Reports Strong Q4 Growth with 26.2% Profit Increase

Sun Pharmaceutical Industries Ltd has reported a significant 26.2% increase in consolidated net profit for the fourth quarter, reaching Rs 2,714.03 crore. This growth is largely attributed to strong formulation sales in India. The company also announced a total revenue of Rs 14,611.79 crore for the quarter, alongside a proposed final dividend of Rs 5 per share. With a full-year net profit of Rs 11,479.42 crore, Sun Pharma's performance reflects notable achievements, including a substantial gain in the Indian market and impressive growth in its innovative medicines segment. The recent acquisition of Organon is expected to further enhance its position in the global pharmaceutical landscape.

By Narendra Chaudhary May 22, 2026, 19:16 IST

Sun Pharmaceutical's Impressive Financial Performance

On May 22, Sun Pharmaceutical Industries Ltd announced a remarkable 26.2% rise in its consolidated net profit, reaching Rs 2,714.03 crore for the fourth quarter ending March 31. This growth is attributed to robust formulation sales in India, compared to Rs 2,149.88 crore during the same period last year, as stated in a regulatory filing.

The company's total revenue from operations for the fourth quarter was Rs 14,611.79 crore, an increase from Rs 12,958.84 crore in the previous year. However, total expenses rose to Rs 11,518.95 crore, up from Rs 9,955.68 crore a year earlier.

Sun Pharma's board has recommended a final dividend of Rs 5 per share for FY26, in addition to the interim dividend of Rs 11 per share, bringing the total dividend for the year to Rs 16 per share, consistent with FY25.

For the fiscal year 2026, the net profit stood at Rs 11,479.42 crore, compared to Rs 10,929.04 crore in FY25, while total revenue from operations reached Rs 58,462.04 crore, up from Rs 52,578.44 crore in the previous fiscal year.

Managing Director Kirti Ganorkar highlighted that the company's full-year performance showcases significant milestones, including a 0.3 percentage point gain in the Indian market, the highest since acquiring Ranbaxy. He noted that the US innovative medicines segment has exceeded USD 1 billion in revenue, with strong growth in markets outside the US. The recent acquisition of Organon is anticipated to further propel Sun's evolution into a prominent global pharmaceutical entity.

In India, formulation sales reached Rs 4,835.9 crore in the fourth quarter, marking a 14.8% increase and representing 33.2% of total consolidated sales. For the entire FY26, sales of formulations in India amounted to Rs 19,290.4 crore, reflecting a 14% year-over-year growth.

Conversely, US formulation sales were USD 459 million, a slight decline of 1.1% in the same quarter, although innovative medicines continued to thrive, balancing the downturn in the generics sector. US sales constituted approximately 28.8% of total consolidated sales in Q4.

For FY26, US formulation sales totaled USD 1,904 million. Global innovative medicines sales reached USD 354 million for Q4FY26, a 20.1% increase, accounting for 22.2% of total sales. For the full year, these sales were USD 1,420 million, up 16.8%.

Additionally, external sales of active pharmaceutical ingredients (API) rose to Rs 673.9 crore, a 26.4% increase in Q4, with total API sales for FY26 at Rs 2,185.3 crore, reflecting a 2.6% growth.